Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune
- Conditions
- HIV Infections
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00979420
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site 28, Freiburg, Germany
🇩🇪Boehringer Ingelheim Investigational Site 36, Hamburg, Germany
🇩🇪Boehringer Ingelheim Investigational Site 37, Hannover, Germany
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT00977431
- Locations
- 🇬🇧
The Royal Marsden Hospital, Sutton, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧The Christie Hospital, Manchester, United Kingdom
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
- First Posted Date
- 2009-09-15
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 42
- Registration Number
- NCT00976950
- Locations
- 🇷🇴
Boehringer Ingelheim Investigational site 17, Brasov, Romania
🇷🇴Boehringer Ingelheim Investigational site 2, Bucuresti, Romania
🇷🇴Boehringer Ingelheim Investigational site 20, Tg.Mures, Romania
Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: placebo matched for fluticasone propionate
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2488
- Registration Number
- NCT00975195
- Locations
- 🇭🇺
352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary
🇭🇺352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
🇭🇺352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT00969553
- Locations
- 🇨🇳
1230.16.886002 Boehringer Ingelheim Investigational Site, Tainan, Taiwan
🇨🇳1230.16.886001 Boehringer Ingelheim Investigational Site, Taipei, Taiwan
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 61
- Registration Number
- NCT00969761
- Locations
- 🇧🇪
1230.6.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1230.6.3202 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
- Conditions
- ThromboembolismArthroplasty, Replacement, Hip
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT00967447
- Locations
- 🇲🇽
Boehringer Ingelheim Investigational Site 11, Distrito Federal, Mexico
🇲🇽Boehringer Ingelheim Investigational Site 15, Distrito Federal, Mexico
🇲🇽Boehringer Ingelheim Investigational Site 12, Distrito Federal, Mexico
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1263
- Registration Number
- NCT00954447
- Locations
- 🇺🇸
1218.36.01005 Boehringer Ingelheim Investigational Site, Statesville, North Carolina, United States
🇦🇷1218.36.54004 Boehringer Ingelheim Investigational Site, Córdoba, Argentina
🇧🇪1218.36.32002 Boehringer Ingelheim Investigational Site, Edegem, Belgium
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT00950742
- Locations
- 🇬🇧
1200.68.44001 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom
🇬🇧1200.68.44003 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom
🇬🇧1200.68.44005 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
- Conditions
- Carcinoma, Non-Small-Cell LungAdenocarcinoma
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 345
- Registration Number
- NCT00949650
- Locations
- 🇦🇷
Imcaba S.R.L., Capital Federal, Argentina
🇩🇪Lungenklinik Hemer, Hemer, Germany
🇧🇷Hospital São Lucas da Pontifícia Universidade Católica, Porto Alegre, Brazil